{"database": "lobbying", "table": "lobbying_activities", "rows": [[3191763, "c1abc650-eef3-4f9f-aa2b-81c860415893", "Q2", "THE OB-C GROUP, LLC", 29802, "EMERGENT BIOSOLUTIONS INC.", 2024, "second_quarter", "DIS", "* Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act * No Specific Bill Number. Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield * No Specific Bill Number. Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines * No Specific Bill Number. State opioid response (SOR) Grant Funding. * No Specific Bill Number. Substance Abuse and Mental Health Block Grants (SABG) funding. * NDAA for Fiscal Year 2024-provisions related to biological and chemical defense and access to naloxone.", "HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2024-07-15T12:17:54-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["3191763"], "units": {}, "query_ms": 6.344925961457193, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}